← Back to Search

Cannabinoid

High Ratio CBD:THC vs. High Ratio THC:CBD Cannabis Oil for Stress and Inhibition in Cannabis Users (CAPU RISE Trial)

Phase 1
Recruiting
Led By Christian G Schütz, MD PhD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have used cannabis for non-medical purposes at least once per week for the past month (30 days), including at least 2 times via oral route of administration
Are 19-35 years old at the start of the study
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion; average of 1 year
Awards & highlights

CAPU RISE Trial Summary

This trial is examining the neurological effects of cannabis on stress reactivity and inhibition in healthy cannabis and stimulant co-users, with the expectation that high ratio CBD:THC cannabis oil will have the largest effect and low ratio CBD:THC cannabis oil will have a moderate effect on outcome measures compared to placebo.

Who is the study for?
This trial is for healthy cannabis users aged 19-35 who frequently use cannabis and alcohol, but do not take certain medications or have conditions that affect the brain, heart, liver, or metal in their body. Participants must be right-handed, non-pregnant, using effective contraception methods and able to attend study sessions.Check my eligibility
What is being tested?
The trial tests how different types of cannabis oil (high THC:CBD ratio vs high CBD:THC ratio) versus a placebo affect stress response and impulse control in regular cannabis users. It's a Phase I study focusing on neurological outcomes.See study design
What are the potential side effects?
Potential side effects may include typical reactions to cannabis such as altered senses or mood changes, dizziness, dry mouth, impaired memory or concentration. Individual responses can vary greatly.

CAPU RISE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have used cannabis weekly for the last month, including twice orally.
Select...
I am between 19 and 35 years old.
Select...
I have received 2 doses of an approved COVID-19 vaccine.
Select...
I have had heavy drinking episodes in the past year.
Select...
I have used at least 20mg of CBD before.
Select...
I have used at least 5mg of THC before.
Select...
I am not trying to become pregnant or using fertility treatments during the study.
Select...
I am between 19 and 35 years old.
Select...
I have not used MDMA/ecstasy/molly.
Select...
I take at least 50 mg of CBD on average.
Select...
I use at least 10 mg of THC on average.
Select...
I will not donate sperm during the study.

CAPU RISE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion; average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion; average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in incidence of adverse events of cannabinoids across conditions
Change in stress response across conditions
Procedure feasibility
+1 more
Secondary outcome measures
Change in performance on behavioral impulsivity tasks across conditions
Change in psychological distress across conditions
Change in sleep quality across conditions
+2 more

CAPU RISE Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: Cannabis oil with a high ratio of THC to CBDActive Control1 Intervention
Participants will be given a single dose of oral cannabis oil containing 5mg THC and 0.17mg CBD.
Group II: Cannabis oil with a high ratio of CBD to THCActive Control1 Intervention
Participants will be given a single dose of oral cannabis oil containing 5mg THC and 25mg CBD.
Group III: PlaceboPlacebo Group1 Intervention
Participants will be given a single dose of 1 mL placebo (carrier oil with botanical terpenes) via oral route of administration.

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,418 Previous Clinical Trials
2,467,098 Total Patients Enrolled
Christian G Schütz, MD PhDPrincipal InvestigatorUniversity of British Columbia; British Columbia Mental Health and Substance Use Services
Karina A Thiessen, BA BEdStudy DirectorUniversity of British Columbia

Media Library

Cannabis oil with a high ratio of CBD to THC (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT05261321 — Phase 1
Healthy Subjects Research Study Groups: Cannabis oil with a high ratio of THC to CBD, Cannabis oil with a high ratio of CBD to THC, Placebo
Healthy Subjects Clinical Trial 2023: Cannabis oil with a high ratio of CBD to THC Highlights & Side Effects. Trial Name: NCT05261321 — Phase 1
Cannabis oil with a high ratio of CBD to THC (Cannabinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05261321 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there potential for harm when patients consume a Cannabis oil with an elevated CBD to THC ratio?

"Our team at Power has classified the safety of cannabis oil with a high ratio of CBD to THC as a 1, since this is an early phase trial and limited data exists regarding its efficacy or security."

Answered by AI

Am I eligible to take part in this clinical study?

"This trial seeks 12 individuals aged 19 to 35 who present as medically healthy. Further, enrollees must have an average Cannabidiol (CBD) intake of at least 50 milligrams and Delta-9-tetrahydrocannabinol (THC) consumption of 10 mg or greater. Additionally, the study requires participants to be exposed to one or more from a list that includes Cocaine, crack cocaine, Methylenedioxymethamphetamine (MDMA/ecstasy/molly), Methamphetamine (meth, ice/crystal meth, speed), Amphetamine (Adderall), Amphetamine/d"

Answered by AI

What are the primary desired outcomes of this research initiative?

"This medical research seeks to measure how often adverse events and subjective effects occur between sessions. It also looks into differences in responses on drug effect questionnaires, standardized mood profiles, and behavioural impulsivity tasks."

Answered by AI

Does this clinical trial accommodate individuals younger than 45 years of age?

"Patients aged 19 to 35 fulfil the eligibility requirements of this experiment; there are 65 studies for participants under 18 years old and 417 trials focused on those who have exceeded retirement age."

Answered by AI

Are there any vacancies for participants in this clinical experiment?

"The trial, which was initially uploaded on November 1st 2022 and last modified October 17th of the same year, is no longer searching for people to participate. Despite this, 952 other clinical trials are presently recruiting participants."

Answered by AI

Who else is applying?

How old are they?
18 - 65
What site did they apply to?
B.R.A.I.N. Lab, Institute of Mental Health, Faculty of Medicine, University of British Columbia
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria

How responsive is this trial?

Typically responds via
Email
Most responsive sites:
  1. B.R.A.I.N. Lab, Institute of Mental Health, Faculty of Medicine, University of British Columbia: < 48 hours
Average response time
  • < 2 Days
~6 spots leftby Dec 2024